"Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s" was originally created and published ...

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm ...

Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and personalized ...

Cognition Therapeutics Reports Improvement In Cognitive Outcomes In Phase 2 SHINE Study In AD. July 29, 2024 — 08:37 am EDT Written by RTTNews.com for RTTNews -> ...

After Recognify Life Sciences Inc.’s phase IIb failure in treating the cognitive impairment in those with schizophrenia, the indication is no closer to a U.S. FDA approved therapy. The ...

INmune Bio Reports Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer’s Disease, Identifying Subpopulations with Cognitive Benefits June 30, 2025 — 07:42 am EDT ...

Two-Phase Study Leads to Monteloeder's Newest Nootropic for Cognitive Performance Provided by PR Newswire Feb 25, 2025 4:00am ...

Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies. Importantly, no evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are ...

The ERUDITE study was the second Phase 2 trial for luvadaxistat. It failed to replicate the cognitive endpoints data seen in the earlier INTERACT™ study, due in part to the large variability ...

“We are excited to advance MT1988 into Phase II trials, where we aim to demonstrate clinical proof of concept in improving cognitive function in patients living with schizophrenia and related ...